The association of antiphospholipid antibodies with cardiopulmonary manifestations of systemic sclerosis

KB Morrisroe; W Stevens; H Nandurkar; D Prior; V Thakkar; J Roddy; J Zochling; J Sahhar; K Tymms; A Sturgess; G Major; F Kermeen; C Hill; J Walker; P Nash; E Gabbay; P Youssef; SM Proudman; M Nikpour

Journal article

The association of antiphospholipid antibodies with cardiopulmonary manifestations of systemic sclerosis

KB Morrisroe, W Stevens, H Nandurkar, D Prior, V Thakkar, J Roddy, J Zochling, J Sahhar, K Tymms, A Sturgess, G Major, F Kermeen, C Hill, J Walker, P Nash, E Gabbay, P Youssef, SM Proudman, M Nikpour

Clinical and Experimental Rheumatology | CLINICAL & EXPER RHEUMATOLOGY | Published : 2014

Abstract

OBJECTIVES: To determine the prevalence and correlates of antiphospholipid antibodies (APLA) in systemic sclerosis (SSc).METHODS: Nine hundred and forty SSc patients were tested for APLA using an ELISA assay at recruitment. Clinical manifestations were defined as present, if ever present from SSc diagnosis. Logistic regression analysis was used to determine the associations of APLA.RESULTS: One or more types of APLA were present in 226 (24.0%) patients. Anticardiolipin (ACA) IgG (ACA-IgG) antibodies were associated with right heart catheter-diagnosed pulmonary arterial hypertension (PAH), with higher titres corresponding with a higher likelihood of PAH (moderate titre (20-39 U/ml) ACA-IgG od..

View full abstract

University of Melbourne Researchers

Wendy Stevens Author

Harshal Nandurkar Author

David Prior Author

Mandana Nikpour Author

Grants

Funding Acknowledgements

Funding was received from the Australian Scleroderma Interest Group, The University of Melbourne, Scleroderma Australia, Arthritis Australia, Actelion, GlaxoSmithKline, Pfizer, Bayer and CSL Biotherapies.M. Nikpour holds a David Bickart Clinician Research Fellowship from the University of Melbourne Faculty of Medicine, Dentistry and Health Sciences.